TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01359046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silver SPC
Description: subject randomized to receive silver alloy impregnated catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard SPC
Description: subject randomized to receive standard catheter
Study: NCT02750579

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention for revascularization
Description: Percutaneous coronary intervention for revascularization with anticoagulant and antiplatelet therapy (routine care)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention for revascularization
Description: Percutaneous coronary intervention for revascularization with anticoagulant and antiplatelet therapy (routine care)
Study: NCT03097614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueTear
Description: The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
Study: NCT04688216

Intervention type: OTHER
Intervention: risk factors of infection with multidrug-resistant organisms
Description: 1. General information: age, gender, length of stay in ICU, method of admission, tubes taken at the time of admission, APACHEⅡ score, surgery, laboratory tests (PCT, CRP, WBC), pressure sores, etc.~2. Iatrogenic factors: days of using ventilator, days of using antibacterial drugs, types of antibacterial drugs, use of glucocorticoids, use of immunosuppressants, days of central venous intubation, days of indwelling catheters, days of arterial catheterization, and other indwelling catheters.~3. The patient's own related factors: diagnosis, whether complicated with hypertension or diabetes; whether exist malignant tumor, primary lung infection, hypoproteinemia; whether antibiotic treatment before admission; fever and fever days, whether diarrhea occurs

Intervention type: OTHER
Intervention: risk factors of infection with multidrug-resistant organisms
Description: 1. General information: age, gender, length of stay in ICU, method of admission, tubes taken at the time of admission, APACHEⅡ score, surgery, laboratory tests (PCT, CRP, WBC), pressure sores, etc.~2. Iatrogenic factors: days of using ventilator, days of using antibacterial drugs, types of antibacterial drugs, use of glucocorticoids, use of immunosuppressants, days of central venous intubation, days of indwelling catheters, days of arterial catheterization, and other indwelling catheters.~3. The patient's own related factors: diagnosis, whether complicated with hypertension or diabetes; whether exist malignant tumor, primary lung infection, hypoproteinemia; whether antibiotic treatment before admission; fever and fever days, whether diarrhea occurs
Study: NCT02348424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solithromycin
Description: Cohorts 1 and 2 will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted). Solithromycin is a fluoroketolide antibiotic under investigation for oral and parenteral use and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solithromycin
Description: Cohorts 1 and 2 will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted). Solithromycin is a fluoroketolide antibiotic under investigation for oral and parenteral use and will be administered orally.
Study: NCT03182127

Intervention type: RADIATION
Group type: OTHER
Intervention: Magnetic resonance imaging
Description: MRI of the elbow is performed in either the supine or prone position A high-resolution surface coil is essential in order to obtain high-quality images . Elbow MRI scanning protocols consist of a combination of T1-weighted and fat-suppressed T2- or proton density-weighted images obtained in the axial, coronal oblique, and sagittal oblique imaging planes. Axial images should extend from the distal humeral diaphysis to the level of the bicipital tuberosity of the radius. From the axial images, coronal oblique images should be prescribed parallel to a line drawn through the centre of the humeral epicondyles, with sagittal oblique images prescribed perpendicular to this. Additional sequences may be helpful in certain circumstances; .

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Description: ultrasound is performed by patient in supine or setting position,applied superficial probe , 2D image and color doppler if indicated.
Study: NCT04328012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: administered 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered 14 days
Study: NCT02228564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Description: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFESTREAM™ covered stent
Description: Implantation of the LIFESTREAM™ covered stent
Study: NCT02120144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation & imagination
Description: It is a combination of an observation phase followed by an immediate imagination phase of a straight gait with an imposed cadency.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reading
Description: A 10 minutes reading phase of François Mauriac's Therese Desqueyroux on a computer
Study: NCT03431909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human urinary kallidinogenase (HUK)
Description: Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
Study: NCT02168062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given SC or IM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03431909

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: aspirin® , clopidogrel® , atorvastatin®
Description: Patients in control group will receive foundation treatment, including aspirin® (100 mg/d), clopidogrel® (75 mg/d), and atorvastatin® (20 mg/d) for 14 days
Study: NCT01765946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablets 500 mg tris in die (tid)
Study: NCT02168062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin Pamoate
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Pamoate
Description: Given IM
Study: NCT01396590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perampanel
Description: 6 x 2 mg perampanel once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perampanel
Description: 12 mg perampanel once per day
Study: NCT00714714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene Gel
Description: adapalene gel 0.3% topically applied daily in a split-face model for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin Gel
Description: Tretinoin 0.1% topically applied daily in a split face model for two weeks
Study: NCT02155010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
Study: NCT01384851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Next Generation Emulsion
Description: One drop both eyes 4 times daily for two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Refresh Dry Eye Therapy
Description: One drop both eyes four times daily for two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Refresh Contacts
Description: One drop both eyes four times daily for two weeks
Study: NCT01718899

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVX-410
Description: Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of a dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVX-410
Description: Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of a dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVX-410
Description: Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of a dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
Study: NCT02781571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg tablet administered orally once daily
Study: NCT02155010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine with heavy bupivacaine
Description: Dexmedetomidine infusion after IT of heavy bupivacaine
Study: NCT00304031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent temozolomide
Description: Daily oral temozolomide (75 mg/m2) up to 49 doses.
Study: NCT01765946

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03661892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syndros
Description: As noted in arm description. For patients who have side effects secondary to Sydnros, the dose will be decreased as below:~Dose subject is taking Reduction recommendation 8.4mg BID Decreased to 8.4mg AM , 4.2mg PM (or it can be 4.2g in AM and 8.4mg in PM- depending on their side effect timing) 8.4mg AM, 4.2mg PM (or vice versa) 4.2mg BID 4.2mg BID 4.2mg once a day 4.2mg once a day Stop and take off study
Study: NCT00776555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate
Description: Study is a two-period cross-over design where subjects will have 2 Screening visits, a Baseline visit, and then be enrolled into the study for 2 Periods. Each Period has 2-3 visits and lasts from 2-6 weeks. At each Period visit subjects will be given one of the two treatment arm drugs that have been solubilized and then have blood drawn for pharmacokinetic analysis and the Drug Rating Questionnaire administered. At the end of Period 1 subjects will be crossed-over to the alternative treatment drug for the Period 2. The Vyvanse™ capsule contents will emptied into water to make a solution and given to subjects to drink at the beginning of each Period visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racemic mixture of dextroamphetamine and lisdexamfetamine
Description: Same visits as described for Vyvanse™. The ADDERALL XR® capsule contents will be crushed, solubilized with water, and given to subjects to drink prior to pharmacokinetic blood draws and DRQ-S administration over the course of two periods.
Study: NCT03554018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 500-1000mg every 6 hours
Study: NCT00416312

Intervention type: DEVICE
Intervention: Patient-specific dosimetry
Description: Tumor absorbed dose calculation using patient-specific 3D-RD dosimetry software.~Patients receive dosimetric tositumomab IV over 60 minutes followed by iodine I 131 (\^131I) tositumomab IV over 20 minutes on day 0. Patients undergo PET/CT scans and SPECT/CT scans on days 0; 2, 3 or 4; and 6 or 7. Patients who have acceptable biodistribution receive therapeutic tositumomab IV over 60 minutes followed by \^131I tositumomab IV over 20 minutes on approximately day 7.

Intervention type: DEVICE
Intervention: conventional dosimetry
Description: Doses calculated using conventional dosimetry software.~Patients receive dosimetric rituximab IV followed by indium In 111 (\^111In) ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo positron emission tomography (PET)/CT scans and single-photon emission computed tomography (SPECT)/CT scans between 2-24, 48-72, and 90-120 hours after \^111In ibritumomab tiuxetan administration. Patients who have acceptable biodistribution receive therapeutic rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes between days 7-9.
Study: NCT00206011

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Description: Open surgical intervention compared to endoscopic intervention

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic surgery
Description: Open surgical intervention compared to endoscopic intervention
Study: NCT00629525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 at a dose of 10 mg PO daily
Study: NCT01853098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Training (PAT)
Description: During the PAT sessions, the participants will be taught the basics of mindfulness and how to concentrate their thoughts and feelings on the present moment in a non-judgmental fashion. As the therapy sessions continue, participants will be introduced to basic loving-kindness meditation (LKM). They will be taught to identify and focus the positive feelings they have when they are around someone or something they care about, and transfer these feelings first to themselves, then to a close friend, to a neutral individual, to people whom they dislike, and finally to all living beings.
Study: NCT01512147

Intervention type: OTHER
Group type: OTHER
Intervention: Isoflurane, Propofol, Dexmedetomidine
Description: We will include following general anesthesia techniques:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250 mcg/kg/min, Isoflurane 0.6% expiratory With this general anesthesia technique we will do our first SSEP/MEP measurements after 30 minutes.~After 30 minutes we will stop isoflurane and will wash out the inhalational anesthetic with high flow air/oxygen and provide:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250mcg/kg/min. This technique will be held for 30 minutes. SSEP/ MEP measurements will be done after 30 minutes.~After the measurements dexmedetomidine will be added with a loading dose of 0.5 mcg/kg over 10 minutes and continuous infusion of 0.5 mcg/kg/hr for 30 minutes.~Fentanyl 1 -2 mcg/kg/hr, Propofol 100 - 250mcg/kg/min, Dexmedetomidine 0.5 mcg/kg/hr.
Study: NCT03554018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Description: Ibuprofen 600mg every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Ibuprofen 600mg every 6 hours

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: To match acetaminophen, patients will take one or two capsules every 6 hours
Study: NCT03557515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management and CBT
Description: Stress Management will focus on:~1. Mind-Body Connection~2. Coping Skills~3. Communication~4. Social Support~Cognitive Behavioral Therapy will focus on:~1. Intro to CBT-Tracking Automatic Thoughts~2. Identifying Distorted Thoughts~3. Challenging Distorted Thoughts~4. Core Beliefs/Relapse Prevention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management and Metta-Meditation
Description: Stress Management will focus on:~1. Mind-Body Connection~2. Coping Skills~3. Communication~4. Social Support~Metta-Meditation will focus on:~1. Intro to Meditation vis Mindfulness of the Breath and Body-Noticing Critical Self Talk~2. Intro to Brief Loving-Kindness Meditation and Self-Care~3. Continuing with Additional Metta-Based Exercises to Cultivate Compassion for Oneself and Others and Mitigating Self-Criticism~4. Review/Plan for Future
Study: NCT00304031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent temozolomide
Description: Daily oral temozolomide (75 mg/m2) up to 49 doses.

Intervention type: DRUG
Group type: OTHER
Intervention: Concurrent temozolomide
Description: Daily oral temozolomide (75 mg/m2) up to 49 doses.
Study: NCT01670175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus, Cyclophosphamide, Topotecan
Description: Dosing of cyclophosphamide and topotecan will be 25 mg/m2/dose and 0.8 mg/ m2 /dose respectively for dose levels 1 and 2. Level 3 dosing will escalate cyclophosphamide to 50 mg/ m2/dose. If level 1 dosing not tolerated, patients will be enrolled in level -1 cohort with cyclophosphamide and sirolimus administered only on days 1-14. If level -1 not tolerated, patients will be enrolled in level -2 with topotecan administration limited to days 1-7.
Study: NCT04522791

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: RFB
Description: The RFB protocol entails a combination of 8 weekly, in-lab training sessions using HRV biofeedback software (Physiocom, Seattle, WA) and daily paced breathing homework using a mobile-based HRV biofeedback app (Inner Balance, HeartMath, LLC, CA).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RFB
Description: The RFB protocol entails a combination of 8 weekly, in-lab training sessions using HRV biofeedback software (Physiocom, Seattle, WA) and daily paced breathing homework using a mobile-based HRV biofeedback app (Inner Balance, HeartMath, LLC, CA).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VSOP
Description: The investigators will use the INSIGHT online program (Posit Science). The platform will be built for our study, including 5 tasks (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice different cognitive processes with PS/A as the shared domain.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: VSOP
Description: The investigators will use the INSIGHT online program (Posit Science). The platform will be built for our study, including 5 tasks (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice different cognitive processes with PS/A as the shared domain.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VSOP
Description: The investigators will use the INSIGHT online program (Posit Science). The platform will be built for our study, including 5 tasks (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice different cognitive processes with PS/A as the shared domain.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: IR
Description: Guided imagery relaxation, equal in dose and frequency to RF practice, will be used to control for relaxation effects that may occur via RFB (which could provide an alternative explanation for outcomes). IR activities will be facilitated using the Insight Timer mobile-based app, which emphasizes the use of visualization and imagery strategies to help the body relax.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IR
Description: Guided imagery relaxation, equal in dose and frequency to RF practice, will be used to control for relaxation effects that may occur via RFB (which could provide an alternative explanation for outcomes). IR activities will be facilitated using the Insight Timer mobile-based app, which emphasizes the use of visualization and imagery strategies to help the body relax.
Study: NCT00936299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion (target dose 300 mg/day) + cognitive behavioral therapy; matched placebo + cognitive behavioral therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01743170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring of self-measured blood pressure
Description: In the intervention group, doctors receive weekly reports via telemonitoring on the self-measured blood pressure
Study: NCT04294654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine 5, 10 and 20 mg/day, tablets, orally Patients will receive 5 mg vortioxetine once daily for one week. At visit 3, the dose will be increased to 10 mg/day for all patients. Thereafter the dose may be adjusted to 5, 10 or 20 mg/day.
Study: NCT02770118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial Sleep Restriction
Description: 4 hour time in bed (TIB), participants will go to bed 4 hours later than during the HS condition. Wake-up times will be the same. During the in-lab portion of the PSR, meals, fulfilling weight-maintenance energy requirements, will be supplied by the research staff as BOOST shakes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial Sleep Restriction
Description: 4 hour time in bed (TIB), participants will go to bed 4 hours later than during the HS condition. Wake-up times will be the same. During the in-lab portion of the PSR, meals, fulfilling weight-maintenance energy requirements, will be supplied by the research staff as BOOST shakes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation
Description: 0 hour time in bed (TIB), participants will remain awake throughout the night. Meals will be provided as BOOST shakes at the same meal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation
Description: 0 hour time in bed (TIB), participants will remain awake throughout the night. Meals will be provided as BOOST shakes at the same meal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habitual Sleep
Description: 8 hours time in bed (TIB), for 3 nights, with fixed bed and wake times, while at home. During the 3-d HS phase, participants will be provided will BOOST meal replacement shakes in amounts required to achieve weight maintenance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habitual Sleep
Description: 8 hours time in bed (TIB), for 3 nights, with fixed bed and wake times, while at home. During the 3-d HS phase, participants will be provided will BOOST meal replacement shakes in amounts required to achieve weight maintenance.